Randomized trial · people

NMN: raised blood NAD over 60 days in 80 middle-aged adults

Checked against the paper Randomized trialPublished by PepVault

The takeaway

In healthy middle-aged adults, daily NMN up to 900 mg raised blood NAD and was well tolerated over 60 days, with the largest NAD and walking gains in the 600 mg and 900 mg arms.

Kind
Randomized trial
Studied in
People
Number studied
80
Published
2023
Journal
Geroscience

What they tested

The team tested whether daily oral NMN raises blood NAD levels in a dose-dependent way, and whether it is safe and affects physical performance and health measures.

How the study was done

A randomized, double-blind, placebo-controlled trial run at several centers in 80 healthy middle-aged adults. Each person took placebo (a dummy dose with no NMN) or 300 mg, 600 mg or 900 mg of NMN once daily by mouth for 60 days.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

PepVault for iPhone

Taking NMN? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

All 80 people finished the trial. Blood NAD rose in all three NMN arms at day 30 and day 60 compared with placebo and with starting levels (all p ≤ 0.001), and it was highest in the 600 mg and 900 mg arms. Gains in six-minute walking distance were larger in all NMN arms than with placebo at both time points (all p < 0.01), longest in the 600 mg and 900 mg arms. Blood biological age, an estimate from the Aging.Ai 3.0 calculator, went up in the placebo arm and held steady in the NMN arms (all p < 0.05), while HOMA-IR, a measure of insulin resistance, did not differ from placebo. No safety issues showed up in side effects, lab tests or clinical checks, and SF-36 general health scores improved more than with placebo in all NMN arms except the 300 mg arm at day 30.

What it doesn’t show

This was a small, short trial of 60 days in healthy middle-aged adults, so it does not show long-term effects or results in older or sick people. Results came from a per-protocol analysis, and biological age was a calculator estimate rather than a direct health outcome.

The paper

Yi et al. The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial. Geroscience. 2023.

The compound

More studies on NMN

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking NMN? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo